ARS Pharmaceuticals, Inc.
SPRYDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
SPRY Earnings Report
EPS Est: $-0.55 | FQ end 2026-06
How SPRY's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ARS-1 | Phase 2 | Asthma | - | - |
0.5 mg epinephrine | Phase 2 | Urticaria Chronic | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ARS Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in ARS Pharmaceuticals, Inc.'s (SPRY) pipeline across Phase 2. Its lead program is ARS-1 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ARS Pharmaceuticals, Inc.'s next FDA catalyst?→
ARS Pharmaceuticals, Inc.'s (SPRY) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SPRY biotech catalysts?→
Add SPRY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ARS Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.